vaccines for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
C4591031- first boost NCT04955626		RCT	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	low	5081/5044	conclusif	demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
C4591031- first boost NCT04955626		RCT	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	low	5081/5044	conclusif	demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
Pfizer/BioNTech Booster study NCT04713553		RCT	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	no results	Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
Pfizer/BioNTech Booster study NCT04713553		RCT	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	no results	Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
COVI3		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 93 % decrease in confirmed COVID (any severity) (PE) suggested 93 % decrease in symptomatic Covid-19
COVI3		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 93 % decrease in confirmed COVID (any severity) (PE) suggested 93 % decrease in symptomatic Covid-19
McConeghy		OBS	first booster dose	mRNA vaccine	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 97 % decrease in deaths,deaths suggested 82 % decrease in hospitalization or death,hospitalization or death suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity) suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
McConeghy		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 97 % decrease in deaths,deaths suggested 82 % decrease in hospitalization or death,hospitalization or death suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity) suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
Thompson		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	critical	2961/989	suggested	suggested 90 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
Agur unpublished		OBS	mRNA vaccine	uncontrolled study	COVID-19 prophylaxis (excluding children)	NA	-/-	no results
Kislaya		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 69 % decrease in confirmed COVID (any severity)
Kislaya		OBS	first booster dose	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 64 % decrease in confirmed COVID (any severity)
Kislaya		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 69 % decrease in confirmed COVID (any severity) suggested 64 % decrease in confirmed COVID (any severity)
Bar-On		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
Bar-On		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
Shemer		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	-/-	inconclusive
Accorsi		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	no results	Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
Accorsi		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	no results	Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
Thompson -VISIOn Network (omicron)		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 81 % decrease in hospitalization suggested 52 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
Thompson -VISIOn Network (omicron)		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 90 % decrease in hospitalization suggested 82 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
UKHSA report week 12 (24 March 2022)		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 88 % decrease in deaths,deaths (time to event analysis only) suggested 83 % decrease in hospitalization
UKHSA report week 12 (24 March 2022)		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	NA	-/-	no results
Abu-Raddad		OBS	first booster dose	Spikevax (Moderna mRNA-1273 COVID-19 vaccine)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
Abu-Raddad		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 77 % decrease in hospitalization or death suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
Abu-Raddad		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 77 % decrease in hospitalization or death suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity) suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
Kirsebom (UKHSA)		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 17 % decrease in symptomatic Covid-19
Arbel		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	serious	758118/85090	suggested	suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
Arbel		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	serious	758118/85090	suggested	suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
Barda		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	728321/728321	suggested	suggested 81 % decrease in deaths suggested 93 % decrease in hospitalization (PE)
Barda		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	728321/728321	suggested	suggested 81 % decrease in deaths suggested 93 % decrease in hospitalization (PE)
CDC Mesa County, Colorado		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	serious	-/-	suggested	suggested 78 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
HEROES-RECOVER (Fowlkes)		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	serious	3483/734	suggested
Martinez-Baz		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 82 % decrease in confirmed COVID (any severity) suggested 95 % decrease in hospitalization,severe COVID-19 occurrence suggested 82 % decrease in symptomatic Covid-19
Pawlowski		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	NA	31069/31069	suggested
Pawlowski		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	NA	-/-	inconclusive
REACT-1 round 13 final report (Elliott, Imperial College London)		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	serious	-/-	suggested	suggested 59 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
Shah		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	serious	-/-	suggested	suggested 55 % decrease in confirmed COVID (any severity) but with a low degree of certainty due to high risk of bias
Shibli		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	-/-	safety concern	statistically significant 36 % increase in Bell's palsy
Tande unpublished		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	-/-	no results
Mattiuzzi		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 85 % decrease in confirmed COVID (any severity) suggested 85 % decrease in hospitalization
Mattiuzzi		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 65 % decrease in confirmed COVID (any severity) suggested 69 % decrease in hospitalization
Lauring		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	5728/5962	suggested	suggested 86 % decrease in hospitalization
Lauring		OBS	first booster dose	mRNA vaccine	COVID-19 prophylaxis (excluding children)	NA	5728/5962	suggested	suggested 94 % decrease in hospitalization
Lauring		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	5728/5962	suggested	suggested 94 % decrease in hospitalization
Lauring		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	5728/5962	suggested	suggested 44 % decrease in death or ventilation suggested 46 % decrease in death or ventilation suggested 76 % decrease in death or ventilation suggested 85 % decrease in hospitalization suggested 85 % decrease in hospitalization suggested 65 % decrease in hospitalization
Ontario (Buchan)		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 37 % decrease in confirmed COVID (any severity)
Patalon		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 85 % decrease in confirmed COVID (any severity) suggested 92 % decrease in hospitalization
Patalon		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 85 % decrease in confirmed COVID (any severity) suggested 92 % decrease in hospitalization
Tenforde		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 97 % decrease in confirmed COVID (any severity)
Tenforde		OBS	first booster dose	mRNA vaccine	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 82 % decrease in hospitalization
Tenforde		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 82 % decrease in hospitalization
Tenforde		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 82 % decrease in confirmed COVID (any severity)
Butt		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	moderate	54360/54360	suggested	suggested 97 % decrease in confirmed COVID (any severity) with a moderate degree of certainty due to some concern in risk of bias
Chung		OBS	mRNA vaccine	control	COVID-19 prophylaxis (excluding children)	NA	53270/270763	suggested	suggested 91 % decrease in symptomatic Covid-19
England (Andrews)		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	581/130867	suggested	suggested 75 % decrease in symptomatic Covid-19,confirmed COVID (any severity) suggested 71 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
Grannis		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	serious	-/-	suggested	suggested 82 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
Li		OBS	Inactivated virus vaccine	control	COVID-19 prophylaxis (excluding children)	critical	74/292	suggested	suggested 59 % decrease in confirmed COVID (any severity) but with a very low degree of certainty due to critical risk of bias
Patalon		OBS	first booster dose	Comirnaty (tozinameran - Pfizer/BIONTECH)	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 79 % decrease in confirmed COVID (any severity)
Patalon		OBS	first booster dose	complete primary vaccine series	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 79 % decrease in confirmed COVID (any severity)
REACT-SCOT		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	NA	111295/1093449	suggested	suggested 61 % decrease in hospitalization or death
Sisonke 2 (booster) NCT05148845		OBS	first booster dose	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 85 % decrease in hospitalization
VA (Bajema)		OBS	vaccines	control	COVID-19 prophylaxis (excluding children)	serious	-/-	suggested
Aleman		DESC	mRNA vaccine	uncontrolled study	COVID-19 prophylaxis (excluding children)	NA	-/-	no results
Boyarsky		DESC	vaccines	uncontrolled study	COVID-19 prophylaxis (excluding children)	NA	-/-	no results
Boyarsky		DESC	mRNA vaccine	uncontrolled study	COVID-19 prophylaxis (excluding children)	NA	-/-	no results

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis